MedicGo
Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population.
Metadata
Journaljournal of clinical investigation11.864Date
2020 Aug 07
a month ago
Type
Journal Article
Volume
2020-Aug-07 / :
Author
Klein SL 1, Pekosz A 1, Park HS 1, Ursin RL 2, Shapiro JR 3, Benner SE 4, Littlefield K 1, Kumar S 5, Naik HM 5, Betenbaugh M 6, Shrestha R 4, Wu AA 4, Hughes RM 4, Burgess I 4, Caturegli P 4, Laeyendecker O 7, Quinn TC 8, Sullivan DJ 9, Shoham S 8, Redd AD 7, Bloch EM 4, Casadevall A 9, Tobian AAR 4
Affiliation
  • 2. Department of Biochemistry and Molecular Biology, Johns Hopkins Bloomberg School of Public Health, Baltimore, United States of America.
  • 3. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, United States of America.
  • 4. Department of Pathology, Johns Hopkins School of Medicine, Baltimore, United States of America.
  • 5. Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, United States of America.
  • 6. Department of Chemical and Biomolecular Engineering, Johns Hopkins Univeristy, Baltimore, United States of America.
  • 7. Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes , Bethesda, United States of America.
  • 8. Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore,, United States of America.
  • 9. Department of Molecular Microbiology and Immunology, Johns Hopkins School of Public Health, Baltimore, United States of America.
Doi
PMIDMESH
Abstract
Convalescent plasma is a leading treatment for COVID-19, but there is a paucity of data identifying therapeutic efficacy. Among 126 potential convalescent plasma donors, the humoral immune response was evaluated by a SARS-CoV-2 virus neutralization assay using Vero-E6-TMPRSS2 cells, commercial IgG and IgA ELISA to spike(S) protein S1 domain (Euroimmun), IgA, IgG and IgM indirect ELISAs to the full-length S or S-receptor binding domain(S-RBD), and an IgG avidity assay. Multiple linear regression and predictive models were utilized to assess the correlations between antibody responses with demographic and clinical characteristics. IgG titers were greater than either IgM or IgA for S1, full length S, and S-RBD in the overall population. Of the 126 plasma samples, 101(80%) had detectable neutralizing antibody(nAb) titers. Using nAb titers as the reference, the IgG ELISAs confirmed between 95-98% of the nAb positive, but only 20-32% of the nAb negative samples. Male sex, older age, and hospitalization with COVID-19 were associated with increased antibody responses across the serological assays. There was substantial heterogeneity in the antibody response among potential convalescent plasma donors, but sex, age, and hospitalization emerged as factors that can be used to identify individuals with a high likelihood of having strong antiviral antibody responses.
Keywords: COVID-19 Immunoglobulins
Fav
Like
Download
Share
Export
Cite
11.9
J Clin Investjournal of clinical investigation
Metadata
LocationUnited States
FromAMER SOC CLINICAL INVESTIGATION INC

No Data

© 2017 - 2020 Medicgo
Powered by some medical students